var data={"title":"Sebelipase alfa: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sebelipase alfa: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/791880?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sebelipase-alfa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sebelipase alfa: Patient drug information&quot;</a> and <a href=\"topic.htm?path=sebelipase-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sebelipase alfa: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45820938\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Kanuma</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759567\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Enzyme, Replacement Therapy</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127920\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Lysosomal acid lipase (LAL) deficiency:</b> IV: 1 mg/kg every other week</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127919\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=sebelipase-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sebelipase alfa: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rapidly progressive lysosomal acid lipase (LAL) deficiency presenting within the first 6 months of life:</b> Infants: IV: Initial: 1 mg/kg once weekly; if response not optimal, may increase to 3 mg/kg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>LAL deficiency:</b> Infants, Children, and Adolescents: IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127921\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>LAL deficiency:</b> Refer to adult dosing; has not been studied.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127922\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127923\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127924\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild or moderate hypersensitivity reaction: Interrupt infusion; consider resuming at slower infusion rate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hypersensitivity reaction or anaphylaxis: Immediately discontinue infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45820939\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kanuma: 20 mg/10 mL (10 mL) [contains albumin human, egg white (egg protein)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45820937\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127939\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer diluted solution as an IV infusion using low&ndash;protein-binding infusion set with in-line, low&ndash;protein-binding 0.2 micron filter. Infuse over at least 2 hours; may consider 1-hour infusion for those patients receiving 1 mg/kg dose who tolerate a 2-hour infusion. Consider further prolonging infusion time for 3 mg/kg dose or if hypersensitivity reaction occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759569\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Lysosomal acid lipase deficiency:</b> Treatment of patients with lysosomal acid lipase (LAL) deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45807204\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined. Incidences are reported for children, adolescents, and adult patients unless specified otherwise.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest discomfort, oxygen saturation decreased (infants), tachycardia (infants)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (28%), anxiety, hypotonia (infants)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Urticaria (infants: 33%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increase in LDL cholesterol (81%; mean increase of 18% at 2 and 4 weeks postinitiation), increased serum triglycerides (58%; mild increases that are transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (infants: 67%), vomiting (infants: 67%), constipation (8%), nausea (8%), retching (infants)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (infants: 44%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction (20%; infants: 64%; children, adolescents, and adults: 13%), anaphylaxis (3%; may be delayed as late as 1 year after treatment initiation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Immunogenicity (infants: &le;57%; neutralizing and may affect drug efficacy: 29%; children, adolescents, and adults: 14%; neutralizing without any association on drug efficacy: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Rhinitis (infants: 56%), cough (infants: 33%), nasopharyngitis (infants: 33%; children and adult patients: 11%), oropharyngeal pain (17%), sneezing (infants)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (infants: 56%; children and adult patients: 25%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759570\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed within the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127905\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity reactions have occurred during infusion and within 4 hours after the infusion. Anaphylaxis has occurred as early as the sixth infusion and as late as 1 year after treatment initiation. During infusion, appropriate medical treatment should be immediately available. Depending on severity of hypersensitivity reaction, management may include temporary interruption, lowering infusion rate, and/or administration of antihistamines, antipyretics, and/or corticosteroids. If interrupted, the infusion may be resumed at a slower rate with increases as tolerated. Pretreatment with antipyretics and/or antihistamines may prevent subsequent reactions in those cases where symptomatic treatment was required. If anaphylaxis or severe hypersensitivity occurs, immediately discontinue infusion and initiate appropriate medical treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: Patients have developed anti-drug antibodies (ADA) to sebelipase alfa and may be more likely to experience hypersensitivity reactions. Some patients with neutralizing antibodies experienced decreased growth velocity. No clear association exists between the development of ADA and decreased efficacy in patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergy to egg or egg products: Sebelipase alfa is produced in egg whites of genetically engineered chickens; consider the risks and benefits in patients with known systemic hypersensitivity reactions to eggs or egg products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45785892\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45785889\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105704&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127903\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Sebelipase alfa is a recombinant form of lysosomal acid lipase (LAL), an essential enzyme required for lipid metabolism (Burton 2015; Shirley 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127904\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sebelipase alfa is excreted in breast milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127941\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs and symptoms of hypersensitivity reaction (during infusion and for at least 4 hours after completion of infusion); lipid panel; anti-drug antibody assessment; hepatic function (ALT).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127910\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sebelipase alfa binds to cell surface receptors via glycans expressed on the protein and is subsequently internalized into lysosomes. Sebelipase alfa catalyzes the lysosomal hydrolysis of cholesteryl esters and triglycerides to free cholesterol, glycerol, and free fatty acids. In patients with lysosomal acid lipase (LAL) deficiency, replacement with sebelipase alfa, a recombinant form of LAL, results in improvement in disease-related hepatic and lipid parameters. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46127912\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-c and triglycerides reduction: Within 8 weeks; a transient increase in these values occurs during first 2 to 4 weeks of treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ALT reduction: Within 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Effects on ALT partially reverse 3 weeks after treatment discontinuation (Balwani 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 to 11 years: 3.6 &plusmn; 3 L</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">12 to 17 years: 5.4 &plusmn; 2.4 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 5.3 &plusmn; 1.6 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Children &ge;4 years, Adolescents, and Adults: Mean range: 5.4 to 6.6 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Children &ge;4 years, Adolescents, and Adults: Mean range: 1.1 to 1.3 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46105224\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Kanuma Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/10 mL (10 mL): $12,252.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45784084\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kanuma (AT, CZ, DE, DK, EE, FI, FR, GB, HR, IE, JP, KR, LT, NO, PL, PT, SE, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Balwani M, Breen C, Enns GM, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. <i>Hepatology</i>. 2013;58(3):950-957. doi:10.1002/hep.26289.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sebelipase-alfa-drug-information/abstract-text/23348766/pubmed\" target=\"_blank\" id=\"23348766\">23348766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burton BK, Balwani M, Feillet F, et al. A Phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. <i>N Engl J Med</i>. 2015;373(11):1010-1020. doi:10.1056/NEJMoa1501365.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sebelipase-alfa-drug-information/abstract-text/26352813/pubmed\" target=\"_blank\" id=\"26352813\">26352813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kanuma (sebelipase alfa) [prescribing information]. Cheshire, CT: Alexion Pharmaceuticals; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shirley M. Sebelipase alfa: first global approval. <i>Drugs</i>. 2015;75(16):1935-1940. doi: 10.1007/s40265-015-0479-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sebelipase-alfa-drug-information/abstract-text/26452566/pubmed\" target=\"_blank\" id=\"26452566\">26452566</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105704 Version 29.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45820938\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45759567\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F46127920\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46127919\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F46127921\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46127922\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46127923\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F46127924\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45820939\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F45820937\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46127939\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45759569\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45807204\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45759570\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46127905\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45785892\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45785889\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46127903\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46127904\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46127941\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46127910\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F46127912\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46105224\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45784084\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/105704|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sebelipase-alfa-patient-drug-information\" class=\"drug drug_patient\">Sebelipase alfa: Patient drug information</a></li><li><a href=\"topic.htm?path=sebelipase-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">Sebelipase alfa: Pediatric drug information</a></li></ul></div></div>","javascript":null}